Post-HTS Case Report and Structural Alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one Actives Verified by ALARM NMR

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2015 Aug 31

PMID 26318992

Citations 5

Authors

Jayme L Dahlin

J Willem M Nissink

Subhashree Francis

Jessica M Strasser

Kristen John

Zhiguo Zhang

Michael A Walters

Affiliations

Soon will be listed here.

Abstract

Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report-including the decision-making process behind the 'no-go' decision-should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

Citing Articles

Fragment screening targeting Ebola virus nucleoprotein C-terminal domain identifies lead candidates.

Aceti D, Ahmed H, Westler W, Wu C, Dashti H, Tonelli M Antiviral Res. 2020; 180:104822.

PMID: 32446802 PMC: 7894038. DOI: 10.1016/j.antiviral.2020.104822.

Repurposing approved drugs on the pathway to novel therapies.

Schein C Med Res Rev. 2019; 40(2):586-605.

PMID: 31432544 PMC: 7018532. DOI: 10.1002/med.21627.

ALARM NMR for HTS triage and chemical probe validation.

Dahlin J, Cuellar M, Singh G, Nelson K, Strasser J, Rappe T Curr Protoc Chem Biol. 2018; 10(1):91-117.

PMID: 30034947 PMC: 6053072. DOI: 10.1002/cpch.35.

Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors.

Dahlin J, Nelson K, Strasser J, Barsyte-Lovejoy D, Szewczyk M, Organ S Nat Commun. 2017; 8(1):1527.

PMID: 29142305 PMC: 5688144. DOI: 10.1038/s41467-017-01657-3.

Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity.

Gilberg E, Stumpfe D, Bajorath J F1000Res. 2017; 6.

PMID: 28928939 PMC: 5596351. DOI: 10.12688/f1000research.12370.2.

References

Gao H, Sun J, Yan C . Four-component reaction of cyclic amines, 2-aminobenzothiazole, aromatic aldehydes and acetylenedicarboxylate. Beilstein J Org Chem. 2014; 9:2934-9. PMC: 3896266. DOI: 10.3762/bjoc.9.330. View

Baell J, Holloway G . New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. DOI: 10.1021/jm901137j. View

Jia J, Xu X, Liu F, Guo X, Zhang M, Lu M . Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening. PLoS One. 2013; 8(4):e59315. PMC: 3615092. DOI: 10.1371/journal.pone.0059315. View

Arnold L, Estebanez-Perpina E, Togashi M, Jouravel N, Shelat A, McReynolds A . Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem. 2005; 280(52):43048-55. DOI: 10.1074/jbc.M506693200. View

Congreve M, Carr R, Murray C, Jhoti H . A 'rule of three' for fragment-based lead discovery?. Drug Discov Today. 2003; 8(19):876-7. DOI: 10.1016/s1359-6446(03)02831-9. View

Burgess R, Zhou H, Han J, Zhang Z . A role for Gcn5 in replication-coupled nucleosome assembly. Mol Cell. 2010; 37(4):469-80. PMC: 2954627. DOI: 10.1016/j.molcel.2010.01.020. View

Dahlin J, Nissink J, Strasser J, Francis S, Higgins L, Zhou H . PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem. 2015; 58(5):2091-113. PMC: 4360378. DOI: 10.1021/jm5019093. View

Nissink J, Blackburn S . Quantification of frequent-hitter behavior based on historical high-throughput screening data. Future Med Chem. 2014; 6(10):1113-26. DOI: 10.4155/fmc.14.72. View

Metz J, Huth J, Hajduk P . Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J Comput Aided Mol Des. 2007; 21(1-3):139-44. DOI: 10.1007/s10822-007-9109-z. View

10.

Soares K, Blackmon N, Shun T, Shinde S, Takyi H, Wipf P . Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol. 2010; 8(2):152-74. PMC: 3098569. DOI: 10.1089/adt.2009.0247. View

11.

McGovern S, Caselli E, Grigorieff N, Shoichet B . A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem. 2002; 45(8):1712-22. DOI: 10.1021/jm010533y. View

12.

Pearce B, Sofia M, Good A, Drexler D, Stock D . An empirical process for the design of high-throughput screening deck filters. J Chem Inf Model. 2006; 46(3):1060-8. DOI: 10.1021/ci050504m. View

13.

Walters W, Namchuk M . Designing screens: how to make your hits a hit. Nat Rev Drug Discov. 2003; 2(4):259-66. DOI: 10.1038/nrd1063. View

14.

Copeland R . Mechanistic considerations in high-throughput screening. Anal Biochem. 2003; 320(1):1-12. DOI: 10.1016/s0003-2697(03)00346-4. View

15.

Hou X, Li R, Li K, Yu X, Sun J, Fang H . Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014; 57(22):9309-22. DOI: 10.1021/jm500692u. View

16.

Huth J, Song D, Mendoza R, Black-Schaefer C, Mack J, Dorwin S . Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. Chem Res Toxicol. 2007; 20(12):1752-9. DOI: 10.1021/tx700319t. View

17.

Gubler H, Schopfer U, Jacoby E . Theoretical and experimental relationships between percent inhibition and IC50 data observed in high-throughput screening. J Biomol Screen. 2012; 18(1):1-13. DOI: 10.1177/1087057112455219. View

18.

Feng B, Shoichet B . A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc. 2006; 1(2):550-3. PMC: 1544377. DOI: 10.1038/nprot.2006.77. View

19.

Zorn J, Wille H, Wolan D, Wells J . Self-assembling small molecules form nanofibrils that bind procaspase-3 to promote activation. J Am Chem Soc. 2011; 133(49):19630-3. PMC: 3253528. DOI: 10.1021/ja208350u. View

20.

Baell J, Walters M . Chemistry: Chemical con artists foil drug discovery. Nature. 2014; 513(7519):481-3. DOI: 10.1038/513481a. View